Mitochondrial Myopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial myopathies are a group of disorders caused by dysfunction in the mitochondria, the cellular powerhouses responsible for ATP production through oxidative phosphorylation. These conditions primarily affect skeletal muscles, causing weakness, exercise intolerance, and a spectrum of clinical manifestations. Mitochondrial myopathies are part of a broader category of mitochondrial diseases, which are among the most common inherited metabolic disorders, affecting approximately 1 in 5,000 individuals worldwide.
The term "mitochondrial myopathy" encompasses several clinical syndromes, including Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), and Leigh syndrome. These disorders result from mutations in either mitochondrial DNA (mtDNA) or nuclear DNA that affect mitochondrial function.
- Progressive muscle weakness: Typically proximal, affecting shoulder and hip muscles
- Exercise intolerance: Early fatigue disproportionate to activity level
- Muscle fatigue: Persistent tiredness, especially after exertion
- Cramping: Muscle cramps, particularly after exercise
- Myalgia: Muscle pain and tenderness
- Ptosis: Drooping eyelids, often bilateral
- External ophthalmoplegia: Limited eye movements, particularly upward gaze
- Facial weakness: Difficulty with facial expressions
- Dysphagia: Difficulty swallowing in some cases
- Respiratory weakness: Risk of respiratory insufficiency in severe cases
- Cardiomyopathy: Hypertrophic or dilated cardiomyopathy
- Cardiac conduction defects: Arrhythmias, heart block
- Sensorineural hearing loss: Progressive hearing impairment
- Endocrine disorders: Diabetes mellitus, hypoparathyroidism
- Renal tubular acidosis: Particularly with MELAS
- Onset before age 20
- Progressive external ophthalmoplegia
- Pigmentary retinopathy
- Cardiac conduction defects
- Cerebellar ataxia
- Progressive ptosis and ophthalmoplegia
- Typically isolated to extraocular muscles
- May be associated with mild proximal weakness
¶ MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)
- Encephalopathy with seizures
- Stroke-like episodes
- Lactic acidosis
- Often associated with m.3243A>G mutation
- Myoclonus (brief, involuntary muscle jerks)
- Epilepsy
- Ataxia
- Ragged-red fibers on muscle biopsy
- Kearns-Sayre syndrome: Single large mtDNA deletions (typically 1.1-10 kb)
- Pearson syndrome: Similar deletions, bone marrow involvement
- m.3243A>G (MT-TL1): MELAS syndrome
- m.8344A>G (MT-TK): MERRF syndrome
- m.8993T>G/C (MT-ATP6): Leigh syndrome, NARP
- m.11777A>G (MT-ND4): LHON
¶ mtDNA Replication and Maintenance
- POLG: Polymerase gamma - most common cause of autosomal recessive mitochondrial disease
- POLG2: Polymerase gamma accessory subunit
- TWNK (PEO1): Twinkle helicase
- RRM2B: Ribonucleotide reductase M2 B
- TK2: Thymidine kinase 2
- DGUOK: Deoxyguanosine kinase
- OPA1: Mitochondrial dynamin GTPase
- PARS2: Pyrroline-5-carboxylate reductase
- GFM1: Translation elongation factor
- TSFM: Mitochondrial translation factor
- Maternal inheritance: mtDNA mutations
- Autosomal recessive: Nuclear DNA mutations
- Autosomal dominant: Some forms of CPEO (e.g., OPA1, TWNK)
- Impaired oxidative phosphorylation (Complex I-V defects)
- Reduced ATP production
- Increased reactive oxygen species (ROS)
- Mitochondrial DNA depletion
- Energy failure in high-demand tissues (muscle, brain, heart)
- Apoptosis (programmed cell death)
- Lactic acidosis from anaerobic metabolism
- Muscle fiber degeneration
- Ragged-red fibers: Accumulation of abnormal mitochondria
- Cytochrome c oxidase (COX) negative fibers: Complex IV deficiency
- Paracrystalline inclusions: Dense mitochondrial inclusions
- Detailed family history (maternal inheritance pattern)
- Neuromuscular examination
- Assessment of extraocular movements
- Cardiac evaluation (ECG, echocardiogram)
- Lactate: Elevated at rest and after exercise
- Pyruvate: Often elevated
- Creatine kinase (CK): May be mildly elevated
- CSF protein: May be elevated in KSS
- mtDNA sequencing
- Targeted nuclear gene panels
- Whole exome sequencing
- Deletion analysis for mtDNA
- Histochemistry: COX/SDH staining
- Ragged-red fibers (Gomori trichrome)
- Electron microscopy
- Immunohistochemistry
- MRI brain for CNS involvement
- MR spectroscopy for lactate
- Cardiac MRI for cardiomyopathy
- Audiometry for hearing loss
- Ophthalmologic examination (retinopathy)
- Endocrine evaluation
- Physical therapy: Maintain strength and mobility
- Occupational therapy: Assistive devices
- Cardiac management: Pacemakers for conduction defects
- Respiratory support: Non-invasive ventilation if needed
- Seizure control: Antiepileptic medications
- L-arginine: May reduce stroke-like episodes in MELAS
- Coenzyme Q10: Electron carrier supplementation
- L-carnitine: May improve mitochondrial function
- Riboflavin: For complex I deficiency
- Dichloroacetate: For lactic acidosis
- Gene therapy trials
- Mitochondrial replacement therapy
- Small molecule mtDNA replication modulators
- Stem cell approaches
- Regular cardiac evaluation
- Pulmonary function tests
- Endocrine screening
- Audiometric testing
- Highly variable depending on genotype and phenotype
- KSS: Progressive, often fatal by age 20-30
- CPEO: Generally stable, slowly progressive
- MELAS: Variable, stroke-like episodes drive prognosis
- Advances in supportive care have improved outcomes
The study of Mitochondrial Myopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gorman GS, et al. Mitochondrial diseases. Lancet Neurology. 2016.
- Parikh S, et al. Diagnosis and management of mitochondrial disease. Contemporary Neurology. 2019.
- Chinnery PF, et al. Mitochondrial disease in adults. Nature Reviews Neurology. 2020.
- Craven L, et al. Mitochondrial replacement therapy. Science. 2022.
- Stoccoro A, et al. Mitochondrial DNA mutations in pathogenesis. Journal of Neurology. 2023.